

WEBSITE DISCLAIMER

Before downloading, printing or viewing the Prospectus, please carefully read this information. By accessing the Prospectus (by clicking on the link below) you agree to and acknowledge that you have read and accept these terms and conditions of access. The information on this page is not part of the Prospectus. If you do not understand it, you should consult your professional adviser without delay.

Important Notice

Paradigm Biopharmaceuticals Limited (ACN 169 346 963) (**Paradigm** or the **Company**) has lodged a prospectus dated 30 October 2023 (**Prospectus**) with the Australian Securities and Investments Commission (**ASIC**) a non-renounceable accelerated institutional and retail entitlement issue of one (1) fully paid ordinary share (**Share**) for every ten (10) Shares held by eligible Shareholders at an issue price of \$0.43 per Share to raise up to approximately \$12,100,000 (before costs) (based on the number of Shares on issue as at the date of this Prospectus), together with three (3) free attaching options exercisable at \$0.65 on or before 30 November 2024 (**Attaching Options**) for every four (4) Shares subscribed for and issued (**Entitlement Offer**).

The Prospectus also contains an offer up to 41,860,466 Shares at an issue price of \$0.43 per Share (together with three (3) Attaching Options for every four (4) Shares subscribed for and issued) to professional, sophisticated and institutional investors to raise up to approximately \$18,000,000 (**Placement Offer**).

The Company has specified a target market (**Target Market**) for investors under the Offer, which is set out in the target market determination available [here](#) (**TMD**). The Prospectus can only be accessed by investors in the TMD.

The Prospectus and TMD are important documents which should be read in their entirety. If, after reading the Prospectus you have questions about the Offer, TMD or any other matter, please contact your professional advisers without delay.

Neither ASIC nor ASX Limited, nor any of their respective officers, take any responsibility for the contents of the Prospectus or the merits of the investment to which the Prospectus relates.

The electronic copy of the Prospectus available on this website does not constitute an offer of, or an invitation to subscribe for, any securities. You may print out a hard copy of the Prospectus from this website or copy the electronic Prospectus on this website into an electronic file for your personal use only. You must not alter the contents of this electronic file in any way.

Alternatively, you may obtain a hard copy of the Prospectus free of charge by contacting the Company by phone on +61 404 216 467 during office hours or by emailing the Company at investorrelations@paradigmbiopharma.com.

To the extent permitted by law, the Company is not liable for any loss incurred from accessing or downloading the Prospectus from this website, including, but not limited to, data corruption or download.

Entitlement and Acceptance

Anyone who wants to take up their entitlement and apply for shortfall securities beyond their entitlement will need to carefully consider the TMD and Prospectus and complete the personalised Entitlement and Acceptance attached to or accompanied by the Prospectus (**Acceptance Form**) or pay the applications monies in accordance with the details set out in the Prospectus and Acceptance Form. The *Corporations Act 2001* (Cth) prohibits any person from passing onto another person an Acceptance Form unless it is attached to or accompanied by a complete and unaltered version of a prospectus.

The Company reserves the right not to accept Acceptance Form or payment of application monies from a person if it has reason to believe that when that person was given access to the electronic Acceptance Form, it was not provided together with the electronic Prospectus and any relevant supplementary or replacement prospectus or any of those documents were incomplete or altered.

If an Acceptance Form is not completed correctly, or if the accompanying payment is the wrong amount, the Company may, in its discretion, still treat the Acceptance Form to be valid. The Company's decision to treat an acceptance as valid, and how to construe, amend or complete the Acceptance Form, will be final.

No Advice

Nothing contained on this website or in the Prospectus constitutes investment, legal, business, tax or other advice. In particular, the information on this website and in the Prospectus does not take into account your financial or investment objectives, financial situation or particular needs. In making an investment decision, you must rely on your own examination of the Company, the securities being offered for and the terms of the offering, including the merits and risks involved. You should consult your professional advisers for investment, legal, business, tax or other advice.

Persons to whom Offer is available

The distribution of the Prospectus, and the offer of Shares and Attaching Options, is restricted outside Australia. In particular, this Prospectus may not be released to US wire services or distributed in the United States except to shareholders who are Institutional Investors.

For legal reasons, the electronic version of the Prospectus accessible through this website is available to persons accessing this website from within:

- (a) Australia or New Zealand for retail Shareholders; and
- (b) Australia, New Zealand, Singapore, Hong Kong, Cayman Islands, the United Kingdom or the United States for institutional Shareholders,

(the **Permitted Jurisdictions**). If you are accessing this website from anywhere outside a Permitted Jurisdiction (as applicable to you), please do not download the electronic version of the Prospectus.

The Prospectus does not constitute an offer, or invitation to apply for, of securities in any jurisdiction where, or to any person to whom, it would not be lawful to issue the Prospectus or to make the offer or invitation. It is the responsibility of any applicant outside a Permitted Jurisdiction (as applicable to them) to ensure compliance with all laws of any country relevant to their applications, and any such applicant should consult their professional advisers as to whether any government or other consents are required, or whether any formalities need to be observed to enable them to apply for and be allotted any securities.

It is not practicable for the Company to comply generally with the securities laws of overseas jurisdictions having regard to the number of overseas shareholders, the number and value of securities those shareholders would be offered and the cost of complying with regulatory requirements in each relevant jurisdiction. Accordingly, the offer pursuant to the Prospectus is only being extended and securities will only be issued to shareholders with a registered address in a Permitted Jurisdiction (as applicable).

Acknowledgement

By clicking "I Accept" below, you acknowledge and agree that:

- You have read and understood the TMD and that you either fall within the Target Market or, if you do not fall within the Target Market, you are accessing the Prospectus for information purposes only and that you will not make an application under the Offer.
- You have read and understood the above terms and conditions to access the electronic version of the Prospectus;
- You are a resident of a Permitted Jurisdiction (as applicable to you) and you are requesting a copy of the Prospectus from within that Permitted Jurisdiction in accordance with the Prospectus;

OR

If you are not a resident of a Permitted Jurisdiction (as applicable to you), you have consulted your professional adviser as to whether any governmental or other consents are required or whether any other formalities need to be considered and followed before accessing the Prospectus; and

- You will not pass onto any other person the Acceptance Form unless it is attached to or accompanied by the complete and unaltered electronic version of the Prospectus and the TMD.

☐ I ACCEPT

DOWNLOAD PROSPECTUS: <https://paradigmbiopharma.com/wp-content/uploads/2023/11/2023-10-PAR-ANREO-and-Placement-Prospectus.pdf>

HOME: <https://paradigmbiopharma.com>